Compile Data Set for Download or QSAR
Report error Found 16 Enz. Inhib. hit(s) with all data for entry = 3525
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35948(4-pyridinoxy-2-anilinopyridine-based compound, 12)
Affinity DataIC50: 4nM EC50:  32nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35949(4-pyridinoxy-2-anilinopyridine-based compound, 13)
Affinity DataIC50: 6nM EC50:  62nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35946(4-pyridinoxy-2-anilinopyridine-based compound, 10)
Affinity DataIC50: 7nM EC50:  114nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35953(4-pyridinoxy-2-anilinopyridine-based compound, 17)
Affinity DataIC50: 12nM EC50:  31nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35941(4-pyridinoxy-2-anilinopyridine-based compound, 5)
Affinity DataIC50: 13nM EC50:  20nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35952(4-pyridinoxy-2-anilinopyridine-based compound, 16)
Affinity DataIC50: 21nM EC50:  27nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35942(4-pyridinoxy-2-anilinopyridine-based compound, 6)
Affinity DataIC50: 35nM EC50:  21nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35955(4-pyridinoxy-2-anilinopyridine-based compound, 19)
Affinity DataIC50: 72nM EC50:  22nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35950(4-pyridinoxy-2-anilinopyridine-based compound, 14)
Affinity DataIC50: 30nM EC50:  35nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35939(4-pyridinoxy-2-anilinopyridine-based compound, 1)
Affinity DataIC50: 44nM EC50:  55nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35954(4-pyridinoxy-2-anilinopyridine-based compound, 18)
Affinity DataIC50: 129nM EC50:  63nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35945(4-pyridinoxy-2-anilinopyridine-based compound, 9)
Affinity DataIC50: 107nM EC50:  628nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35944(4-pyridinoxy-2-anilinopyridine-based compound, 8)
Affinity DataIC50: 108nM EC50:  282nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35951(4-pyridinoxy-2-anilinopyridine-based compound, 15)
Affinity DataIC50: 109nM EC50:  146nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35943(4-pyridinoxy-2-anilinopyridine-based compound, 7)
Affinity DataIC50: 227nM EC50: >5.80E+3nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed
TargetTGF-beta receptor type-1(Human)
Astrazeneca

LigandPNGBDBM35947(4-pyridinoxy-2-anilinopyridine-based compound, 11)
Affinity DataIC50: 739nM EC50: >3.00E+3nMpH: 7.4 T: 2°CAssay Description:A fluorescence polarization assay was used to assess the ALK5 binding capacity and biochemical activity of compounds. ALK5 protein was added to each ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/17/2009
Entry Details Article
PubMed